Rescula® Eye Drops was approved in Japan in 1994 as the world’s first prostaglandin metabolite medicine to treat glaucoma and ocular hypertension. The drug is now approved in 45 countries worldwide and is marketed in Japan by Santen Pharmaceutical Co., Ltd., Taiwan and Korea by Astellas Pharma Inc. and in the rest of the world by Novartis Pharma AG.
R-Tech Ueno provides basic strategies for marketing and promotion of the product in Japan.

For further information, please contact: